Urinary angiotensinogen level is associated with potassium homeostasis and clinical outcome in patients with polycystic kidney disease: a prospective cohort study

Table 2 Logistic regression analysis for the risk of hyperkalemia according to etiology of CKD

CKD subcohort	Unadjusted		Model 1		Model 2		Model 3
CKD subcohort	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
PKD	(Reference)		(Reference)		(Reference)		(Reference)
DN	9.52 (6.02–15.06)	< 0.001	8.77 (4.74–16.24)	< 0.001	4.65 (2.42–8.93)	< 0.001	4.91 (2.54–9.50)	< 0.001
HTN	3.42 (2.10–5.57)	< 0.001	3.47 (2.07–5.83)	< 0.001	2.54 (1.50–4.30)	0.001	2.57 (1.51–4.37)	< 0.001
GN	2.79 (1.76–4.42)	< 0.001	2.92 (1.82–4.66)	< 0.001	1.70 (1.03–2.81)	0.038	1.82 (1.10–3.03)	0.02
Unclassified	4.57 (2.55–8.17)	< 0.001	4.59 (2.44–8.65)	< 0.001	2.86 (1.48–5.53)	0.002	2.95 (1.52–5.72)	0.001

Model 1: adjusted age, sex, history of DM, BMI, and SBP
Model 2: Model 1 + serum sodium and UPCR*
Model 3: Model 2 + use of RAAS blockade, diuretics, CCB, and beta blockers
*Data were log transformed
Abbreviations: CKD Chronic kidney disease, OR odds ratio, CI Confidence interval, PKD Polycystic kidney disease, DN Diabetic nephropathy, HTN Hypertensive nephrosclerosis, GN, glomerulonephritis; eGFR, estimated glomerular filtration rate; BMI Body mass index; SBP, systolic blood pressure; UPCR, urine protein-to-creatinine ratio; RAAS, renin-angiotensin-aldosterone system; CCB, calcium channel blocker

ISSN: 1471-2369